Protonitazepyne

Protonitazepyne
Identifiers
	IUPAC name 5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazole;
PubChem CID	168322728;
ChemSpider	115005635;
Chemical and physical data
Formula	C23H28N4O3
Molar mass	408.502 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCOC1=CC=C(C=C1)CC2=NC3=C(N2CCN4CCCC4)C=CC(=C3)[N+](=O)[O-];
	InChI InChI=1S/C23H28N4O3/c1-2-15-30-20-8-5-18(6-9-20)16-23-24-21-17-19(27(28)29)7-10-22(21)26(23)14-13-25-11-3-4-12-25/h5-10,17H,2-4,11-16H2,1H3; Key:KCRWXNIIXGBPID-UHFFFAOYSA-N;

Protonitazepyne (N-pyrrolidino protonitazene) is a benzimidazole derivative with opioid effects, which has been sold as a designer drug over the internet, first being mentioned in mid 2022 and definitively identified in drug seizures in Canada in early 2023. It is an analogue of etonitazene where the ethoxy group has been extended to propoxy, and the N,N-diethyl substitution has been cyclised into a pyrrolidine ring. While formal studies into its pharmacology have yet to be carried out, it is believed to be slightly less potent than the ethoxy analogue etonitazepyne but still a potent opioid.^[1]^[2]

References[edit]

^ "Early signal alert: Emergence of online mentions of Protonitazepyne". National Drug Early Warning System. 29 July 2022.
^ "Analyzed Drug Report" (PDF). Drug Analysis Service and Cannabis Laboratories. Health Canada. April–June 2023.

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

[1] "Early signal alert: Emergence of online mentions of Protonitazepyne". National Drug Early Warning System. 29 July 2022.

[2] "Analyzed Drug Report" (PDF). Drug Analysis Service and Cannabis Laboratories. Health Canada. April–June 2023.

[1]

[2]

See also[edit]

References[edit]